--Preclinical data for Cimeio’s CD45 universal heme ADC and shielded HSCs demonstrate effective depletion of an aggressive AML cell line in vivo-- --First data for Cimeio’s CD33 shielded HSCs show ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results